ArticleCerebellum (London, England)2026
Gluten Ataxia in Children and Adolescents.
Article in Cerebellum (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurological manifestations of gluten sensitivity (GS) with gluten ataxia (GA) are well-recognised in adults. We present our experience in children and adolescents (C/A) seen with suspected GS, mainly GA, over a 5-year period. Retrospective case note analysis was performed on clinical, serological andneuroimaging data of 20 C/A seen in our specialist ataxia referral centre withsuspected NGS. 14 female and 6 male C/A (range: 6-15 years, median: 12.5 years) were referred to our specialist ataxia clinic with suspected GS. All 20 patients had motor coordination/balance difficulties with ataxia. Headaches were present in 12/20 C/A (60%), sensory neuropathic symptoms in 6/20 C/a (30%), postural dizziness in 6/20 (30%). 8/20 C/A (40%) had pre-existing autism spectrum disorder (ASD). Family history of GS/GA/Coeliac disease was present in 10/20 C/A (50%). Serological abnormalities were present in all 20 CYP, with raised antibodies: antigliadin in 15/20 (75%), transglutaminase-6 in 12/20 (60%), transglutaminase-2 in 7/20 (35%), and endomysial in 4/20 (20%). MR Spectroscopy of the cerebellum showed a reduced N-acetylaspartate: Creatine (NAA/Cr) ratio in 14/20 (70%). 18/20 (90%) received a gluten-free diet (GFD). 13/18 (72%) of C/A reported improvement of symptoms on GFD. We suggest considering GS as a differential diagnosis in the presence of motor coordination difficulties with abnormal MRS of the cerebellum and raised antigliadin and/or transglutaminase-6 antibodies. Early diagnosis of GS is important, as it is a treatable cause of childhood ataxia.Further follow-up will help in defining the natural history and GS in C/A.
Indexed as
Identifiers
42518048What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.